Recombinant α-galactosidase A (ERT)
Agalsidase beta
Brand names: Fabrazyme
Adult dose
Dose: 1 mg/kg every 2 weeks
Route: IV infusion
Frequency: Fortnightly
Clinical pearls
- Fabry disease ERT; pre-medicate per protocol; commissioned through specialist LSDU service
Contraindications
- Life-threatening hypersensitivity
Side effects
- Infusion reactions (fever, rigors, chest tightness)
- Headache
Interactions
- Avoid chloroquine/amiodarone (theoretical)
Monitoring
- Renal function (eGFR, proteinuria)
- Cardiac function
- Antibodies
Reference: BNF; NHS England LSDU; SmPC Fabrazyme. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- MAGGIC Heart Failure Risk Score · Heart Failure
- Long QT Syndrome (Schwartz Score) · Channelopathy / Sudden Cardiac Death
- C-Peptide to Glucose Ratio · Diabetes Classification
- International Staging System (ISS) for Multiple Myeloma · Multiple Myeloma
- Revised ISS (R-ISS) for Multiple Myeloma · Haematological Malignancy
- International Staging System for Multiple Myeloma (ISS) · Oncology